UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
of the
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 15, 2007
CHINA BIOPHARMACEUTICALS HOLDINGS, INC.
------------------------------
(Exact name of registrant as specified in its charter)
Delaware 814-00063 13-2949462
-------- --------- ----------
(State or other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
Suite 602, China Life Tower
16 Chaowai Street, Chaoyang Dist.
Beijing, China 100020
--------------------------
(Address of principal executive offices)
86-10-85251616
-------------------------------------
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 4.02 NON-RELIANCE ON PREVIOUSLY ISSUED FINANCIAL STATEMENTS OR A RELATED
AUDIT REPORT OR COMPLETED INTERIM REVIEW.
On March 15, 2007, due to the legal action process as described in the Company's
current report on Form 8-K filed on March 19, 2007, the board of directors of
the Company believes that there maybe adjustments and additional disclosures
that will be required to be made to the Company's quarterly reports on Form
10QSB and that it is the Company's responsibility to inform the public not to
rely on the financial statements contained in the Company's quarterly reports on
Form 10QSB for the interim periods ended June 30, 2006 and September 30, 2006,
which included the financial position and operations of Shenyang Enshi
Pharmaceutical Co., Ltd, and are subject to amendments. Pending the results of
investigation and legal actions, the Company will provide further updates in its
future filings.
The board of the directors of the Company has discussed with the Company's
auditor, Moore Stephens Wurth Frazer and Torbet, LLP such non-reliance and
amendments of the aforementioned financial statements.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
China Biopharmaceuticals Holdings, Inc.
By: /s/ Chris Peng Mao
-----------------------------
Name: Chris Peng Mao
Title: Chief Executive Officer
Dated: April 3, 2007